针对孕妇的X受体,使用一种基于强激素的PROTAC来延缓结肠癌复发
Lucile Bansard1, Guillaume Laconde2, Vanessa Delfosse3
1Institute of Functional Genomics (IGF), Univ. Montpellier, Inserm, CNRS, Montpellier, France.
Oncogenesis
|August 30, 2025
概括
一种新的PROTAC分子JMV7048向并降解癌细胞中的Pregnane X受体 (PXR). 在临床前模型中,这种方法使化疗耐药的瘤重新敏感,并防止癌症复发.
科学领域:
- 癌症学
- 分子生物学
- 药物发现
背景情况:
- 瘤复发通常与耐药癌细胞有关.
- 降低孕妇X受体 (PXR) 的调节可以降低化疗抵抗,防止复发.
- 需要临床可行的PXR抗剂.
研究的目的:
- 使用PROTAC方法设计和合成一种新的PXR抗剂.
- 评估PROTAC降解PXR和使癌细胞对化疗的有效性.
主要方法:
- 基于PXR激活剂的PROTAC的设计和合成 (JMV7048).
- 通过ubiquitination和proteasome途径进行PXR降解的评估
- 对JMV7048对癌细胞系 (结肠癌,肝癌,胰腺癌) 和人类原发性肝细胞的影响的评估.
- 在异种移植小鼠模型中进行测试,以评估化学抵抗性和复发预防性.
主要成果:
- JMV7048有效促进人体PXR蛋白的多化和降解.
- 在各种癌细胞系中观察到选择性PXR降解,不影响主要肝细胞.
- 药物耐受性结肠癌细胞的PXR表达减少使它们对化疗敏感.
- 在异种移植模型中观察到癌症复发的显著延迟.
结论:
- 像JMV7048这样的PXR向的PROTAC是一种有前途的治疗策略.
- 这种方法可以提高抗化疗癌症对化疗的敏感性.
- 提供一种新途径来预防瘤复发.
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
251
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
251
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
259
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
259
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
321
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
321
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
264
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
264


